Les essais cliniques de médicaments de thérapie innovante: quel avenir pour la réglementation européenne?

Abstract : In relation to the “hot” topic of regenerative medicine, European Union law established a specific legal framework for advanced therapy medicinal products, manufactured from human or animal genes, cells or tissues. However, these medicinal products do not have always to be submitted to clinical trials as legal requirements vary according to the intended use: market of the whole of Member States, compassionate use, and hospital exemption. Moreover, specificities of these medicinal products make clinical trials difficult to be conducted. This paper highlights the consecutive competition between regulations and products that takes roots in the tension between the challenges of patients’ safety and quick access to innovative treatments. It also shows the regulatory flexibility currently favored to ensure the necessary balance between safety and availability, is not without limits.
Document type :
Journal articles
Complete list of metadatas

Cited literature [2 references]  Display  Hide  Download

https://halshs.archives-ouvertes.fr/halshs-01856035
Contributor : Aurélie Mahalatchimy <>
Submitted on : Thursday, August 9, 2018 - 1:13:04 PM
Last modification on : Friday, April 12, 2019 - 2:26:15 PM
Long-term archiving on : Saturday, November 10, 2018 - 12:49:09 PM

File

ArticleMTI-JIB-Final.pdf
Files produced by the author(s)

Identifiers

Collections

Citation

Aurélie Mahalatchimy, Nathalie de Grove-Valdeyron. Les essais cliniques de médicaments de thérapie innovante: quel avenir pour la réglementation européenne?. Journal International de Bioéthique, ESKA, 2018, Les médicaments innovants / Innovative drugs, 29 (2), pp.35-51. ⟨http://eska-publishing.com/fr/journal-international-de-bioethique/1132904-ib2018200-consulter-le-numero-2-regards-croises-sur-l-embryon-40-ans-apres-la-loi-veil.html⟩. ⟨10.3917/jibes.292.0035⟩. ⟨halshs-01856035⟩

Share

Metrics

Record views

141

Files downloads

1208